Medication info

Hiroza Tablet

Prescription medicationTabletOralExpired
Ingredient · strength
Losartan Potassium›50mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Samchundang Pharmaceutical Co., Ltd.
Appearance
Yellow oval film-coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Expired

MFDS item code 200607805 · Notified 2006.07.26

This product's status changed to Expired on 2024.07.01. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension not controlled by monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg daily are not recommended. The maximum blood pressure-lowering effect generally occurs around 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine when monotherapy does not produce the expected effect. 1. Substitution therapy: A combination regimen of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Thereafter, continue to monitor the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose in patients with a creatinine clearance of 30 mL/min or greater. Administration is not recommended in patients with more severe renal impairment, because loop diuretics are preferable to thiazide drugs in these patients. ○ Patients with hepatic impairment Use is not recommended in these patients because this medicine cannot provide the 25 mg initial dose of losartan potassium for patients with hepatic impairment who require dose adjustment.
Child dose
○ Children (under 18 years of age) Because there is no experience with use in children and adolescents, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
Samchundang Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled by monotherapy

  • Hypertension
View approved original text

This medication is used in patients with hypertension whose blood pressure is not adequately controlled with monotherapy.

How to take

Adult dose

○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg daily are not recommended. The maximum blood pressure-lowering effect generally occurs around 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine when monotherapy does not produce the expected effect. 1. Substitution therapy: A combination regimen of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Thereafter, continue to monitor the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose in patients with a creatinine clearance of 30 mL/min or greater. Administration is not recommended in patients with more severe renal impairment, because loop diuretics are preferable to thiazide drugs in these patients. ○ Patients with hepatic impairment Use is not recommended in these patients because this medicine cannot provide the 25 mg initial dose of losartan potassium for patients with hepatic impairment who require dose adjustment.

Child dose

○ Children (under 18 years of age) Because there is no experience with use in children and adolescents, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during pregnancy, especially during the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. This medication should not be taken if there is a hypersensitivity to it, specific kidney diseases, liver diseases, electrolyte imbalances, or if pregnant. Patients with hypotension or impaired kidney function, elderly patients, and diabetic patients should use this medication cautiously and have their blood pressure, kidney function, and electrolyte status regularly monitored during treatment. This medication can affect blood potassium levels, so it should not be taken with potassium supplements or potassium-containing medications, and potential drug interactions may occur, so consultation with a doctor or pharmacist is recommended. Dizziness or drowsiness may occur during treatment, so caution is needed when driving or operating machinery. If symptoms of hypersensitivity such as skin reactions, difficulty breathing, or swelling of the face or lips occur, discontinue use immediately and seek medical attention. There is insufficient experience with this medication in children and adolescents, so it should not be administered to them. For storage, keep in a place out of reach of children and securely sealed in its original container.

Side effects

  • Craniosynostosis
  • Anuria
  • Hypotension
  • Renal failure
  • Death
  • Abdominal pain
  • Edema
  • Palpitations
  • Back pain
  • Dizziness
Show 148 more
  • Cough
  • Sinusitis
  • Upper respiratory infection
  • Rash
  • Angioedema
  • Skin exfoliation
  • Hemolysis
  • Chest pain
  • Facial edema
  • Fever
  • Orthostatic hypotension
  • Syncope
  • Angina pectoris
  • Arrhythmia
  • Cerebrovascular accident
  • Hypotension
  • Myocardial infarction
  • Secondary atrioventricular block
  • Loss of appetite
  • Constipation
  • Toothache
  • Dry mouth
  • Indigestion
  • Flatulence
  • Gastritis
  • Vomiting
  • Fatigue
  • Anemia
  • Gout
  • Arm pain
  • Arthralgia
  • Arthritis
  • Fibromyalgia
  • Hip pain
  • Joint swelling
  • Knee pain
  • Leg pain
  • Muscle cramps
  • Muscle weakness
  • Musculoskeletal pain
  • Myalgia
  • Shoulder pain
  • Muscle rigidity
  • Anxiety
  • Anxiety disorder
  • Ataxia
  • Confusion
  • Depression
  • Nightmares
  • Sensory disturbances
  • Insomnia
  • Reduced libido
  • Memory impairment
  • Migraine
  • Hyperesthesia
  • Panic disorder
  • Dysesthesia
  • Peripheral neuropathy
  • Sleep disorder
  • Drowsiness
  • Tremor
  • Dizziness
  • Dyspnea
  • Epistaxis
  • Nasal congestion
  • Pharyngeal discomfort
  • Respiratory congestion
  • Rhinitis
  • Venous sinus disorder
  • Chest discomfort
  • Alopecia
  • Dermatitis
  • Dry skin
  • Purpura
  • Erythema
  • Flushing
  • Photosensitivity reaction
  • Pruritus
  • Sweating
  • Urticaria
  • Blurred vision
  • Ocular pain
  • Burning sensation
  • Conjunctivitis
  • Visual impairment
  • Taste disorders
  • Tinnitus
  • Erectile dysfunction
  • Nocturia
  • Pollakiuria
  • Urinary tract infection
  • Weakness
  • Pancreatitis
  • Jaundice
  • Salivary gland inflammation
  • Spasms
  • Gastrointestinal irritation
  • Aplastic anemia
  • Agranulocytosis
  • Leukopenia
  • Hemolytic anemia
  • Thrombocytopenia
  • Purpura
  • Necrotizing vasculitis
  • Pneumonia
  • Pulmonary edema
  • Acute respiratory distress syndrome
  • Hyperglycemia
  • Diabetes
  • Hyperuricemia
  • Muscle cramps
  • Agitation
  • Renal failure
  • Renal dysfunction
  • Interstitial nephritis
  • Stevens-Johnson syndrome
  • Erythema multiforme
  • Toxic epidermal necrolysis
  • Temporary blurred vision
  • Xanthopsia
  • Acute myopia
  • Acute angle-closure glaucoma
  • Hypotension
  • Tachycardia
  • Hypokalemia
  • Hypochloremia
  • Hyponatremia
  • Polydipsia
  • Thirst
  • Weak
  • Drowsiness
  • Drowsiness
  • Agitation
  • Confusion
  • Seizures
  • Myalgia
  • Muscle fatigue
  • Decreased urine output
  • Tachycardia
  • Nausea
  • Vomiting
  • Vasculitis
  • Anaphylactic reaction
  • Hepatitis
  • Erythema multiforme
  • Hyperkalemia
  • Hyponatremia
  • Rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container that blocks light and kept at a temperature between 1 and 30 degrees Celsius. Storing it this way will help maintain the medication's effectiveness for a long time.

Appearance and packaging

Appearance

Yellow oval film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.